TCMD (Tactile Systems Technology, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by TCMD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-13 | Elaine M. Birkemeyer | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2026-05-08 | Laura G. King | Director | A | — | — |
| 2026-05-08 | Carmen B Volkart | Director | A | — | — |
| 2026-05-08 | Raymond Huggenberger | Director | A | — | — |
| 2026-05-08 | Valerie L. Asbury | Director | A | — | — |
| 2026-05-08 | WILLIAM W BURKE | Director | A | — | — |
| 2026-05-08 | Andrea Pearson | Director | A | — | — |
| 2026-05-08 | David Brent Shafer | Director | A | — | — |
| 2026-05-08 | Boyd Vindell Washington | Director | A | — | — |
| 2026-03-11 | Andrea Pearson | Director | A | — | — |
| 2026-02-26 | Elaine M. Birkemeyer | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2026-02-26 | Kristie Burns | Sr. VP Mktg & Clinical Affairs | Sell | — | — |
| 2026-02-26 | Sheri Louise Dodd | Chief Executive Officer | Sell | — | — |
| 2026-02-24 | Elaine M. Birkemeyer | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-02-24 | Sheri Louise Dodd | Chief Executive Officer | MIXED | — | — |
| 2026-02-24 | Kristie Burns | Sr. VP Mktg & Clinical Affairs | MIXED | — | — |
| 2026-02-23 | Kristie Burns | Sr. VP Mktg & Clinical Affairs | A | — | — |
| 2026-02-23 | Sheri Louise Dodd | Chief Executive Officer | A | — | — |
| 2026-02-23 | Elaine M. Birkemeyer | CHIEF FINANCIAL OFFICER | A | — | — |
| 2026-01-06 | Kristie Burns | Sr. VP Mktg & Clinical Affairs | Sell | — | — |
| 2025-08-12 | Sheri Louise Dodd | Chief Executive Officer | Sell | — | — |
| 2025-05-14 | Elaine M. Birkemeyer | Chief Financial Officer | Sell | — | — |
| 2025-05-12 | Sheri Louise Dodd | Chief Executive Officer | Sell | — | — |
| 2025-05-09 | Valerie L. Asbury | Director | A | — | — |
| 2025-05-09 | Laura G. King | Director | A | — | — |
| 2025-05-09 | Carmen B Volkart | Director | A | — | — |
| 2025-05-09 | David Brent Shafer | Director | A | — | — |
| 2025-05-09 | WILLIAM W BURKE | Director | MIXED | — | — |
| 2025-05-09 | Raymond Huggenberger | Director | A | — | — |
| 2025-05-09 | Boyd Vindell Washington | Director | A | — | — |
| 2025-03-13 | DANIEL L. REUVERS | Director | G | — | — |
| 2025-02-27 | Kristie Burns | Sr. VP Mktg & Clinical Affairs | Sell | — | — |
| 2025-02-27 | DANIEL L. REUVERS | Director | Sell | — | — |
| 2025-02-27 | Elaine M. Birkemeyer | Chief Financial Officer | Sell | — | — |
| 2025-02-24 | Elaine M. Birkemeyer | Chief Financial Officer | MIXED | — | — |
| 2025-02-24 | Laura G. King | Director | A | — | — |
| 2025-02-24 | Sheri Louise Dodd | Chief Executive Officer | A | — | — |
| 2025-02-24 | DANIEL L. REUVERS | Director | MIXED | — | — |
| 2025-02-24 | Kristie Burns | Sr. VP Mktg & Clinical Affairs | MIXED | — | — |
| 2024-08-14 | Sherri Lee Ferstler | Senior VP, Sales | Sell | — | — |
| 2024-08-09 | Sheri Louise Dodd | Chief Executive Officer | A | — | — |
| 2024-05-20 | Elaine M. Birkemeyer | Chief Financial Officer | Sell | — | — |
| 2024-05-10 | David Brent Shafer | Director | A | — | — |
| 2024-05-10 | Valerie L. Asbury | Director | A | — | — |
| 2024-05-10 | Sheri Louise Dodd | Director | A | — | — |
| 2024-05-10 | Boyd Vindell Washington | Director | A | — | — |
| 2024-05-10 | Raymond Huggenberger | Director | A | — | — |
| 2024-05-10 | WILLIAM W BURKE | Director | MIXED | — | — |
| 2024-05-10 | Carmen B Volkart | Director | A | — | — |
| 2024-05-08 | Kristie Burns | Sr. VP Mktg & Clinical Affairs | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 4,280,688 | — |
| — | 10%+ Owner | 3,985,233 | — |
| — | 10%+ Owner | 907,736 | — |
| — | Chief Executive Officer | 288,822 | — |
| — | Chief Executive Officer | 243,885 | — |
| — | President and CEO | 214,604 | — |
| — | CHIEF FINANCIAL OFFICER | 130,188 | — |
| — | Director | 118,677 | — |
| — | Sr. VP Mktg & Clinical Affairs | 82,581 | — |
| — | Director | 81,193 | — |
| — | 10%+ Owner | 80,396 | — |
| — | Chief Operating Officer | 76,032 | — |
| — | Director | 68,550 | — |
| — | Vice President, Reimbursement | 66,790 | — |
| — | Director | 62,841 | — |
| — | Director | 59,837 | — |
| — | Director | 55,343 | — |
| — | Director | 55,343 | — |
| — | Director | 55,041 | — |
| — | Chief Financial Officer | 55,004 | — |
| — | Chief Financial Officer | 48,760 | — |
| — | Director | 44,219 | — |
| — | Director | 41,768 | — |
| — | Senior VP, Sales | 38,764 | — |
| — | SVP, Sales | 37,567 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TCMD quote page; the site-wide leaderboard is on the insider transactions hub.